Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Li, Hui ^a   Wang, Xi ^a   Mao, Yiqing ^a   Hu, Ruobi ^a   Xu, Wei ^a   Lei, Zhen ^d   Zhou, Na ^a   Jin, Ling ^a   Guo, Tingting ^a   Li, Zhixin ^a   Irwin, David M ^c   Niu, Gang ^b   Tan, Huanran ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Beijing N and N Genetech Company   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

AMPK; Diabetic cardiomyopathy; Insulin receptor; Liver specific glucokinase knockout; Rosiglitazone

Indexed keywords

ADENOSINE 5' MONOPHOSPHATE ACTIVATED PROTEIN KINASE; GLUCOKINASE; INSULIN; INSULIN RECEPTOR; MYOSIN LIGHT CHAIN 2; PROTEIN KINASE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; DRUG EFFECT; ELECTROCARDIOGRAM; ELECTRON MICROSCOPY; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE WALL; HEART MUSCLE; HEART MUSCLE FIBROSIS; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MITOCHONDRIAL VOLUME DENSITY; MITOCHONDRION; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; TRANSTHORACIC ECHOCARDIOGRAPHY;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIABETIC CARDIOMYOPATHIES; DOWN-REGULATION; GLUCOKINASE; LIVER; MICE; MICE, KNOCKOUT; NADPH OXIDASE; RANDOM ALLOCATION; RECEPTOR, INSULIN; TIME FACTORS; UP-REGULATION;

EID: 84892665408     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-24     Document Type: Article

References (51)

1. Voulgari C, Papadogiannis D, Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag 2010, 6:883-903. 2964943, 21057575.
2. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010, 11:31-39. 10.1007/s11154-010-9131-7, 2914514, 20180026.
3. Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail 2010, 16:971-979. 10.1016/j.cardfail.2010.07.249, 21111987.
4. Nunes S, Soares E, Pereira FC, Reis F. The role of inflammation in diabetic cardiomyopathy. Int J Infereron Cytokine Mediator Res 2012, 4:59-73.
5. Fredersdorf S, Thumann C, Zimmermann WH, Vetter R, Graf T, Luchner A, Riegger GA, Schunkert H, Eschenhagen T, Weil J. Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data. Cardiovasc Diabetol 2012, 11:57. 10.1186/1475-2840-11-57, 3447673, 22621761.
6. Hou L, Lian K, Yao M, Shi Y, Lu X, Fang L, He T, Jiang L. Reduction of n-3PUFAs, specifically DHA and EPA, and enhancement of peroxisomal beta oxidation in type 2 diabetic rat heart. Cardiovasc Diabetol 2012, 11:126. 10.1186/1475-2840-11-126, 3490815, 23057715.
7. Aragno M, Mastrocola R, Ghé C, Arnoletti E, Bassino E, Alloatti G, Muccioli G. Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms. Cardiovasc Diabetol 2012, 11:129. 10.1186/1475-2840-11-129, 3537569, 23066908.
8. Nunes S, Soares E, Fernandes J, Viana S, Carvalho E, Pereira FC, Reis F. Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide over expression seems to be the best marker. Cardiovasc Diabetol 2013, 12:44. 10.1186/1475-2840-12-44, 3599663, 23497124.
9. Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model Mech 2009, 2:454-466. 10.1242/dmm.001941, 19726805.
10. Toye AA, Moir L, Hugill A, Bentley L, Quarterman J, Mijat V, Hough T, Goldsworthy M, Haynes A, Hunter AJ, Browne M, Spurr N, Cox RD. A new mouse model of type 2 diabetes, produced by N-ethyl-nitrosourea mutagenesis, is the result of a missense mutation in the glucokinase gene. Diabetes 2004, 53:1577-1583. 10.2337/diabetes.53.6.1577, 15161764.
11. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001, 345:971-980. 10.1056/NEJMra002168, 11575290.
12. Froguel P, Velho G. Molecular genetics of maturity-onset diabetes of the young. Trends Endocrinol Metab 1999, 10:142-146. 10.1016/S1043-2760(98)00134-9, 10322408.
13. Inoue M, Sakuraba Y, Motegi H, Kubota N, Toki H, Matsui J, Toyoda Y, Miwa I, Terauchi Y, Kadowaki T, Shigeyama Y, Kasuga M, Adachi T, Fujimoto N, Matsumoto R, Tsuchihashi K, Kagami T, Inoue A, Kaneda H, Ishijima J, Masuya H, Suzuki T, Wakana S, Gondo Y, Minowa O, Shiroishi T, Noda T. A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program. Hum Mol Genet 2004, 13:1147-1157. 10.1093/hmg/ddh133, 15102714.
14. van Bürck L, Blutke A, Kautz S, Rathkolb B, Klaften M, Wagner S, Kemter E, de Hrabé Angelis M, Wolf E, Aigner B, Wanke R, Herbach N. Phenotypic and pathomorphological characteristics of a novel mutant mouse model for maturity-onset diabetes of the young type 2 (MODY 2). Am J Physiol Endocrinol Metab 2010, 298:E512-E523. 10.1152/ajpendo.00465.2009, 19952346.
15. Zhang YL, Tan XH, Xiao MF, Li H, Mao YQ, Tan HR. Establishment of liver specific glucokinase gene knockout mice: a new animal model for screening anti-diabetic drugs. Acta Pharmacol Sin 2004, 25:1659-1665.
16. Hemmeryckx B, Hoylaerts MF, Gallacher DJ, Rong Lu H, Himmelreich U, D'hooge J, Swinnen M, Lijnen HR. Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice?. Eur J Pharmacol 2013, 700:23-31. 10.1016/j.ejphar.2012.11.062, 23228931.
17. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170:1191-1201.
18. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418. 10.1001/jama.2010.920, 20584880.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
20. Bugger H, Riehle C, Jaishy B, Wende AR, Tuinei J, Chen D, Soto J, Pires KM, Boudina S, Theobald HA, Luptak I, Wayment B, Wang X, Litwin SE, Weimer BC, Abel ED. Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. J Molec Cell Cardiology 2012, 52:1019-1026.
21. England J, Loughna S. Heavy and light roles: myosin in the morphogenesis of the heart. Cell Mol Life Sci 2013, 70:1221-1239. 10.1007/s00018-012-1131-1, 3602621, 22955375.
22. Velho G, Froguel P. Genetic, metabolic and clinical characteristics of maturity onset diabetes of the young. Eur J Endocrinol 1998, 138:233-239. 10.1530/eje.0.1380233, 9539292.
23. Velho G, Vaxillaire M, Boccio V, Charpentier G, Froguel P. Diabetes complications in NIDDM kindreds linked to the MODY3 locus on chromosome 12q. Diabetes Care 1996, 19:915-919. 10.2337/diacare.19.9.915, 8875082.
24. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 2001, 48:81-86. 10.1507/endocrj.48.81, 11403106.
25. Shigematsu Y, Hamada M, Nagai T, Nishimura K, Inoue K, Suzuki J, Ogimoto A, Higaki J. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance. J Cardiol 2011, 58:18-25. 10.1016/j.jjcc.2011.03.001, 21515029.
26. Vecoli C, Andreassi MG, Liga R, Colombo MG, Coceani M, Carpeggiani C, L'Abbate A, Neglia D. T(-786)C polymorphism of the endothelial nitric oxide synthase gene is associated with insulin resistance in patients with ischemic or non ischemic cardiomyopathy. BMC Med Gene 2012, 13:92-98.
27. Weterman MA, Barth PG, van Spaendonck-Zwarts KY, Aronica E, Poll-The BT, Brouwer OF, van Tintelen JP, Qahar Z, Bradley EJ, de Wissel M, Salviati L, Angelini C, van den Heuvel L, Thomasse YE, Backx AP, Nürnberg G, Nürnberg P, Baas F. Recessive MYL2 mutations cause infantile type I muscle fibre disease and cardiomyopathy. Brain 2013, 136:282-293. 10.1093/brain/aws293, 23365102.
28. Koka S, Xi L, Kukreja RC. Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. Basic Res Cardiol 2012, 107:249-253.
29. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001, 37:1943-1949. 10.1016/S0735-1097(01)01230-X, 11401136.
30. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006, 98:596-605. 10.1161/01.RES.0000207406.94146.c2, 16543510.
31. Teupe C, Rosak C. Diabetic cardiomyopathy and diastolic heart failure - difficulties with relaxation. Diabetes Res Clin Pract 2012, 97:185-194. 10.1016/j.diabres.2012.03.008, 22502812.
32. Christopher CL, Mathuram LN, Genitta G, Cyrus I, Sundar SJ. O mega-3 polyunsaturated fatty acids inhibit the accumulation of PAS-positive material in the myocardium of STZ-diabetic wistar rats. Int J Cardiol 2003, 88:183-190. 10.1016/S0167-5273(02)00393-5, 12714197.
33. Watanabe K, Thandavarayan RA, Harima M, Sari FR, Gurusamy N, Veeraveedu PT, Mito S, Arozal W, Sukumaran V, Laksmanan AP, Soetikno V, Kodama M, Aizawa Y. Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Curr Cardiol Rev 2010, 6:280-290. 10.2174/157340310793566145, 3083809, 22043204.
34. Sourris KC, Harcourt BE, Tang PH, Morley AL, Huynh K, Penfold SA, Coughlan MT, Cooper ME, Nguyen TV, Ritchie RH, Forbes JM. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type2 diabetes. Free Radic Biol Med 2012, 52:716-723. 10.1016/j.freeradbiomed.2011.11.017, 22172526.
35. Wold LE, Ceylan-Isik AF, Ren J. Oxidative stress and stress signaling: menace of diabetic cardio myopathy. Acta Pharmacol Sin 2005, 26:908-917. 10.1111/j.1745-7254.2005.00146.x, 16038622.
36. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 2011, 51:1289-1301. 10.1016/j.freeradbiomed.2011.06.033, 3163726, 21777669.
37. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008, 102:488-496. 10.1161/CIRCRESAHA.107.162800, 18096818.
38. Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy-fact or fiction?. Herz 2011, 36:102-115. 10.1007/s00059-011-3429-4, 21424347.
39. Mashimo K, Sato S, Ohno Y. Chronic effects of ethanol on cultured myocardial cells: ultrastructural and morphometric studies. Virchows Arch 2003, 442:356-363.
40. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 2007, 115:909-917. 10.1161/CIRCULATIONAHA.106.662296, 17261654.
41. Gulick T, Cresci S, Caira T, Moore DD, Kelly KP. The peroxisome proliferator activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A 1994, 91:11012-11016. 10.1073/pnas.91.23.11012, 45156, 7971999.
42. Falcão-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 2012, 17:325-344. 10.1007/s10741-011-9257-z, 21626163.
43. Sack MN. Type 2 diabetes, mitochondrial biology and the heart. J Mol Cell Cardiol 2009, 46:842-849. 10.1016/j.yjmcc.2009.02.001, 2683201, 19217910.
44. Duncan JG. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 1813, 2011:1351-1359.
45. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790. 10.1038/35008121, 10783895.
46. Huynh K, McMullen JR, Julius TL, Tan JW, Love JE, Cemerlang N, Kiriazis H, Du XJ, Ritchie RH. Cardiac-specific insulin-like growth factor 1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 2010, 59:1512-1520. 10.2337/db09-1456, 2874713, 20215428.
47. Hardie DG, John WS, David AP, Emma RH. Management of cellular energy by the AMP activated protein kinase system. FEBS Lett 2003, 546:113-120. 10.1016/S0014-5793(03)00560-X, 12829246.
48. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005, 1:15-25. 10.1016/j.cmet.2004.12.003, 16054041.
49. Saha AK, Ruderman NB. Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol Cell Biochem 2003, 253:65-70. 10.1023/A:1026053302036, 14619957.
50. Saha AK, Schwarsin AJ, Roduit R, Masse F, Kaushik V, Tornheim K, Prentki M, Ruderman NB. Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-beta -Dribofuranoside. J Biol Chem 2000, 275:24279-24283. 10.1074/jbc.C000291200, 10854420.
51. Ruderman N, Prentki M. AMP kinase and malonyl-CoA: targets for therapy of themetabolic syndrome. Nat Rev Drug Discov 2004, 3:340-351. 10.1038/nrd1344, 15060529.